Pediatric Oncologist @LHSCCanada, Program Director (co) Pediatrics @WesternUPaeds, AYA advocate, parent, photographer for fun, foodie | views are my own
Up to 50% of patients with ALL will fail Car T cell therapy. Failure is multifactorial. Poor blinatumomab response is associated with CarT failure
@WorldSIOP#siop2024
The future (and present) of ALL therapy is Blinatumomab .. this is very clear. But innovative therapies are expensive. Our responsibility is to make blin available for all including LMIC. How to do this remains a challenge.
@WorldSIOP#SIOP2024
“Holding complex, flexible and diverse hopes enables patients to believe in the unlikely while simultaneously accepting the inevitable” .. reflecting on this quote as a clinician taking care of patients and families navigating advanced cancer
@ayaprogram#ayaoncology
To all health care providers interested in attending our AYA Health Care Professional Training Day! Please register by using this eventbrite link: https://t.co/se6b9Vlzv3